MARKET

MRUS

MRUS

Merus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.25
+0.51
+2.24%
Opening 11:24 03/08 EST
OPEN
23.00
PREV CLOSE
22.74
HIGH
23.47
LOW
22.23
VOLUME
20.20K
TURNOVER
--
52 WEEK HIGH
31.27
52 WEEK LOW
10.18
MARKET CAP
904.09M
P/E (TTM)
-7.9214
1D
5D
1M
3M
1Y
5Y
Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mar 08, 2021 (GLOBE NEWSWIRE via COMTEX) -- UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 (GLOBE...
GlobeNewswire · 3h ago
Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 3d ago
InvestorNewsBreaks - Merus N.V. (NASDAQ: MRUS) Secures $138M in Underwritten Public Offering
Feb 03, 2021 (Investor Brand Network via COMTEX) -- Merus (NASDAQ: MRUS), focused on the development of innovative, full-length multispecific antibodies, has...
Investor Brand Network · 02/03 18:13
Merus participera aux prochaines conferences des investisseurs
UTRECHT (Pays-Bas) et CAMBRIDGE, Massachusetts (États-Unis), 01 févr. 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une societe d'oncologie au stade clinique qui developpe des anticorps multispecifiques de pleine longueur innovants (Biclonics(R) e...
Globe Newswire · 02/01 20:36
Merus nimmt an Anlegerkonferenzen teil
UTRECHT, Niederlande und CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ: MRUS), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische volllange Antikorper (Biclonics(R) und Triclonics(TM)) entwi...
Globe Newswire · 02/01 20:36
Merus participera aux prochaines conferences des investisseurs
UTRECHT (Pays-Bas) et CAMBRIDGE, Massachusetts (États-Unis), 01 févr. 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS), une societe d'oncologie au stade clinique qui developpe des anticorps multispecifiques de pleine longueur innovants (Biclonics(R) e...
Globe Newswire · 02/01 20:36
Merus nimmt an Anlegerkonferenzen teil
UTRECHT, Niederlande und CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ: MRUS), ein Unternehmen aus dem Bereich der klinischen Onkologie, das innovative multispezifische volllange Antikorper (Biclonics(R) und Triclonics(TM)) entwi...
Globe Newswire · 02/01 20:36
Merus to Participate in Upcoming Investor Conferences
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bil...
GlobeNewswire · 02/01 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRUS. Analyze the recent business situations of Merus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRUS stock price target is 24.14 with a high estimate of 32.00 and a low estimate of 15.00.
EPS
Institutional Holdings
Institutions: 62
Institutional Holdings: 24.66M
% Owned: 63.42%
Shares Outstanding: 38.89M
TypeInstitutionsShares
Increased
14
1.81M
New
15
2.18M
Decreased
10
136.10K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.18%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Non-Executive Chairman/Independent Director
Anand Mehra
President/Chief Executive Officer/Chief Financial Officer/Executive Director
Sven Lundberg
Non-Executive Vice Chairman/Non-Executive Director
Gregory Perry
Chief Technology Officer
John de Kruif
General Counsel
Peter Silverman
Other
Alexander Bakker
Other
Lex Bakker
Other
Andrew Joe
Other
Hui Liu
Non-Executive Independent Director
Mark Iwicki
Other
L. Andres Sirulnik
Non-Executive Independent Director
Leonard Kanavy
Non-Executive Independent Director
Paolo Pucci
Non-Executive Independent Director
Victor Sandor
No Data
About MRUS
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Webull offers kinds of Merus NV stock information, including NASDAQ:MRUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRUS stock methods without spending real money on the virtual paper trading platform.